Pfizer Acknowledges the Death of a Young Boy Who Died One Year After Participating in its Phase II Clinical Trial to Treat DMD
source: shutterstock.com

Pfizer Acknowledges the Death of a Young Boy Who Died One Year After Participating in its Phase II Clinical Trial to Treat DMD

Pfizer has recently paused its Phase III clinical trial that has been assessing the Duchenne muscular dystrophy candidate fordadistrogene movaparvovec. The Phase II DAYLIGHT trial (NCT05429372), enrolled ten boys ages…

Continue Reading Pfizer Acknowledges the Death of a Young Boy Who Died One Year After Participating in its Phase II Clinical Trial to Treat DMD
FDA Approves Dosage Boost for Lambert-Eaton Myasthenic Syndrome Drug FIRDAPSE
source: shutterstock.com

FDA Approves Dosage Boost for Lambert-Eaton Myasthenic Syndrome Drug FIRDAPSE

According to a story from Globe Newswire, the biopharmaceutical company Catalyst Pharmaceuticals has recently announced an update to the company's supplemental New Drug Application (sNDA) for its drug amifampridine (marketed…

Continue Reading FDA Approves Dosage Boost for Lambert-Eaton Myasthenic Syndrome Drug FIRDAPSE
FDA Removes Clinical Hold on Nomlabofusp Study for Friedreich’s Ataxia
source: pixabay.com

FDA Removes Clinical Hold on Nomlabofusp Study for Friedreich’s Ataxia

Three years after the U.S. Food and Drug Administration (FDA) first placed a full clinical hold on Larimar Therapeutics’ Phase 2 clinical study, the hold has officially been lifted. The…

Continue Reading FDA Removes Clinical Hold on Nomlabofusp Study for Friedreich’s Ataxia
ICYMI: FDA Approves BKEMV, A Soliris Biosimilar, for aHUS and PNH
source: shutterstock.com

ICYMI: FDA Approves BKEMV, A Soliris Biosimilar, for aHUS and PNH

Have you ever heard of a biosimilar? A biosimilar is essentially a biologic that is highly similar in structure and function to a reference product. Although this might seem technical, it really…

Continue Reading ICYMI: FDA Approves BKEMV, A Soliris Biosimilar, for aHUS and PNH
The Impact of Artificial Intelligence: Predicting Visual Acuity in DME Following Vabysmo Treatment
Photo by Colin Lloyd on Unsplash

The Impact of Artificial Intelligence: Predicting Visual Acuity in DME Following Vabysmo Treatment

Artificial intelligence (AI) is changing the way we live. It seems rare to find an industry where AI has not made at least a preliminary impact. In politics, AI-generated cartoons…

Continue Reading The Impact of Artificial Intelligence: Predicting Visual Acuity in DME Following Vabysmo Treatment
Rare Community Profiles: A New Treatment Option on the Horizon: Zevra Therapeutics’ Dan Gallo Discusses Arimoclomol, the NDA PDUFA Date, and the Needs of the NPC Community
Fotocitizen / Pixabay

Rare Community Profiles: A New Treatment Option on the Horizon: Zevra Therapeutics’ Dan Gallo Discusses Arimoclomol, the NDA PDUFA Date, and the Needs of the NPC Community

  Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families, advocates, scientists, and more.…

Continue Reading Rare Community Profiles: A New Treatment Option on the Horizon: Zevra Therapeutics’ Dan Gallo Discusses Arimoclomol, the NDA PDUFA Date, and the Needs of the NPC Community
World Pneumothorax Day 2024: Spreading Rare Disease Awareness
source: pixabay.com

World Pneumothorax Day 2024: Spreading Rare Disease Awareness

June 24, 2024 is being recognized as World Pneumothorax Day, a time for spreading awareness about pneumothorax among the general public and in the medical field. Pneumothorax is a condition…

Continue Reading World Pneumothorax Day 2024: Spreading Rare Disease Awareness
Tardive Dyskinesia: Phase 3 Study Results Indicate Improvement with Use of INGREZZA®
source: pixabay.com

Tardive Dyskinesia: Phase 3 Study Results Indicate Improvement with Use of INGREZZA®

This week Neurocrine Biosciences announced the results of its KINECT®-4 Phase 3 study of INGREZZA® capsules. Results of the trial were published in the Journal of Clinical Psychopharmacology. A long-term…

Continue Reading Tardive Dyskinesia: Phase 3 Study Results Indicate Improvement with Use of INGREZZA®
Cartesian Therapeutics Earns Regenerative Medicine Advanced Therapy Designation for Myasthenia Gravis
shutterstock.com

Cartesian Therapeutics Earns Regenerative Medicine Advanced Therapy Designation for Myasthenia Gravis

Cartesian Therapeutics, Inc., a biotechnology company, recently announced that the FDA has awarded the Regenerative Medicine Advanced Therapy (RMAT) designation to its lead product, Descartes-08, to treat myasthenia gravis (MG).…

Continue Reading Cartesian Therapeutics Earns Regenerative Medicine Advanced Therapy Designation for Myasthenia Gravis
Healthy Skin Transplants Could Successfully Treat Epidermolytic Ichthyosis and Ichthyosis with Confetti
source: shutterstock.com

Healthy Skin Transplants Could Successfully Treat Epidermolytic Ichthyosis and Ichthyosis with Confetti

You've heard of kidney transplants. You've heard of liver transplants. And you've probably even heard of lung transplants. But have you heard of skin transplants? In many cases, skin transplants…

Continue Reading Healthy Skin Transplants Could Successfully Treat Epidermolytic Ichthyosis and Ichthyosis with Confetti
Rare Community Profiles: White Paper Discusses Access Barriers in IgG4-Related Disease (IgG4-RD)
Fotocitizen / Pixabay

Rare Community Profiles: White Paper Discusses Access Barriers in IgG4-Related Disease (IgG4-RD)

  Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families, advocates, scientists, and more.…

Continue Reading Rare Community Profiles: White Paper Discusses Access Barriers in IgG4-Related Disease (IgG4-RD)
ICYMI: Neuraxpharm and Minoryx’s Special Information Film Raises Leukodystrophy Awareness
source: pixabay.com

ICYMI: Neuraxpharm and Minoryx’s Special Information Film Raises Leukodystrophy Awareness

Rare Disease Day may be long past in February, but the fight for rare disease awareness continues. Earlier this year, specialty pharmaceutical company Neuraxpharm Group ("Neuraxpharm") and biotechnology company Minoryx…

Continue Reading ICYMI: Neuraxpharm and Minoryx’s Special Information Film Raises Leukodystrophy Awareness
Physicians Identify Poor Disease Management in Patients with IBD
source: shutterstock.com

Physicians Identify Poor Disease Management in Patients with IBD

Effective disease management in inflammatory bowel disease (IBD), which encompasses Crohn’s disease and ulcerative colitis, is incredibly important. Managing your condition helps you maintain a better quality-of-life, reduces uncomfortable or…

Continue Reading Physicians Identify Poor Disease Management in Patients with IBD
Can We Go Too Far with Self-Care?
source: shutterstock.com

Can We Go Too Far with Self-Care?

If you have read my books or articles, you have probably noticed that I talk about self-care quite a bit. I think self-care is extremely important for anyone, whether they…

Continue Reading Can We Go Too Far with Self-Care?